Moreover, antibiotic use has been correlated with poorer outcome in tumor-carrying mice and metastatic RCC and NSCLC patients treated with anti-PD-1 and anti-CTLA-4 antibodies [17, 20, 23]. The gene discussed is PDCD1; the disease is neoplasm.